World's Best Scientists 2026 revealed!

D-Index & Metrics

Medicine

D-Index
99
Citations
53681
World Ranking
8428
National Ranking
121

Overview

Javier Cortes is affiliated with Vall d'Hebron Hospital Universitari in Spain and has published extensively in the medical field, particularly focusing on oncology and breast cancer research.

Their research primarily spans the fields of Medicine, with 1,148 publications, and Biochemistry, Genetics, and Molecular Biology, covering 293 works. Key subfields include Oncology (655 publications), Pulmonary and Respiratory Medicine (295), Cancer Research (202), Radiology, Nuclear Medicine and Imaging (88), and Molecular Biology (63). This range highlights a broad engagement with clinical and molecular aspects of cancer research.

The main topics explored in their work include:

  • Advanced Breast Cancer Therapies
  • HER2/EGFR in Cancer Research
  • Cancer Treatment and Pharmacology
  • Breast Cancer Treatment Studies
  • Cancer Immunotherapy and Biomarkers
  • Cancer Genomics and Diagnostics
  • Monoclonal and Polyclonal Antibodies Research

Among their frequent co-authors are Antonio Llombart-Cussac, Hope S. Rugo, José Manuel Pérez-García, Giuseppe Curigliano, and Peter Schmid, indicating a collaborative research network in oncology and breast cancer treatment.

Javier Cortes has contributed to several notable papers, including:

  • "Pembrolizumab for Early Triple-Negative Breast Cancer" (2020) published in New England Journal of Medicine
  • "Pembrolizumab plus chemotherapy versus placebo plus chemotherapy for previously untreated locally recurrent inoperable or metastatic triple-negative breast cancer (KEYNOTE-355): a randomised, placebo-controlled, double-blind, phase 3 clinical trial" (2020) published in The Lancet
  • "Sacituzumab Govitecan in Metastatic Triple-Negative Breast Cancer" (2021) published in New England Journal of Medicine
  • "5th ESO-ESMO international consensus guidelines for advanced breast cancer (ABC 5)" (2020) published in Annals of Oncology
  • "ESMO Clinical Practice Guideline for the diagnosis, staging and treatment of patients with metastatic breast cancer" (2021) published in Annals of Oncology

The most frequent publication venues for Javier Cortes include Cancer Research, Annals of Oncology, Journal of Clinical Oncology, ESMO Open, and Clinical Cancer Research, reflecting a focus on cancer and oncology-centric journals.

In addition to research articles, they have contributed to book publications such as "Por una nueva historia de la familia en México" (2024) published by Universidad Autónoma de Aguascalientes eBooks.

Best Publications

  • Pertuzumab plus Trastuzumab plus Docetaxel for Metastatic Breast Cancer

    José Baselga;Javier Cortés;Sung-Bae Kim;Seock-Ah Im

  • Pertuzumab, Trastuzumab, and Docetaxel in HER2-Positive Metastatic Breast Cancer

    Sandra M. Swain;José Baselga;Sung-Bae Kim;Jungsil Ro

  • Pembrolizumab for Early Triple-Negative Breast Cancer.

    Peter Schmid;Javier Cortes;Lajos Pusztai;Heather McArthur

  • Trastuzumab Deruxtecan in Previously Treated HER2-Positive Breast Cancer

    Shanu Modi;Cristina Saura;Toshinari Yamashita;Yeon Hee Park

  • Sacituzumab Govitecan in Metastatic Triple-Negative Breast Cancer

    Aditya Bardia;Sara A Hurvitz;Sara M Tolaney;Delphine Loirat

  • Pembrolizumab plus chemotherapy versus placebo plus chemotherapy for previously untreated locally recurrent inoperable or metastatic triple-negative breast cancer (KEYNOTE-355): a randomised, placebo-controlled, double-blind, phase 3 clinical trial.

    Javier Cortes;David W Cescon;Hope S Rugo;Zbigniew Nowecki

  • Pertuzumab plus trastuzumab in combination with standard neoadjuvant anthracycline-containing and anthracycline-free chemotherapy regimens in patients with HER2-positive early breast cancer: a randomized phase II cardiac safety study (TRYPHAENA)

    A. Schneeweiss;S. Chia;T. Hickish;V. Harvey

  • Phase III Study of Bevacizumab Plus Docetaxel Compared With Placebo Plus Docetaxel for the First-Line Treatment of Human Epidermal Growth Factor Receptor 2–Negative Metastatic Breast Cancer

    David W. Miles;Arlene Chan;Luc Y. Dirix;Javier Cortés

  • Eribulin monotherapy versus treatment of physician's choice in patients with metastatic breast cancer (EMBRACE): A phase 3 open-label randomised study

    Javier Cortes;Joyce O'Shaughnessy;David Loesch;Joanne J.L. Blum

  • Pertuzumab, trastuzumab, and docetaxel for HER2-positive metastatic breast cancer (CLEOPATRA study): overall survival results from a randomised, double-blind, placebo-controlled, phase 3 study

    Sandra M Swain;Sung-Bae Kim;Javier Cortés;Jungsil Ro

  • Expression of p95HER2, a Truncated Form of the HER2 Receptor, and Response to Anti-HER2 Therapies in Breast Cancer

    Maurizio Scaltriti;Federico Rojo;Alberto Ocaña;Judit Anido

  • Phase II Trial of Pertuzumab and Trastuzumab in Patients With Human Epidermal Growth Factor Receptor 2–Positive Metastatic Breast Cancer That Progressed During Prior Trastuzumab Therapy

    José Baselga;Karen A. Gelmon;Shailendra Verma;Andrew Wardley

  • Cerebrospinal fluid-derived circulating tumour DNA better represents the genomic alterations of brain tumours than plasma

    Leticia De Mattos-Arruda;Leticia De Mattos-Arruda;Leticia De Mattos-Arruda;Regina Mayor;Charlotte K. Y. Ng;Britta Weigelt

  • Pembrolizumab monotherapy for previously treated metastatic triple-negative breast cancer: cohort A of the phase II KEYNOTE-086 study.

    Sylvia Adams;Peter Schmid;Hope H.S. Rugo;Eric Winer

  • Pertuzumab, trastuzumab, and docetaxel for HER2-positive metastatic breast cancer (CLEOPATRA): end-of-study results from a double-blind, randomised, placebo-controlled, phase 3 study

    Sandra M Swain;Sandra M Swain;David Miles;Sung-Bae Kim;Young-Hyuck Im

  • Early Adaptation and Acquired Resistance to CDK4/6 Inhibition in Estrogen Receptor-Positive Breast Cancer.

    Maria Teresa Herrera-Abreu;Marta Palafox;Uzma Asghar;Martín A Rivas

  • MONARCH 1, A Phase II Study of Abemaciclib, a CDK4 and CDK6 Inhibitor, as a Single Agent, in Patients with Refractory HR+/HER2− Metastatic Breast Cancer

    Maura N. Dickler;Sara Tolaney;Hope S. Rugo;Javier Cortés

  • PI3K Inhibition Impairs BRCA1/2 Expression and Sensitizes BRCA-Proficient Triple-Negative Breast Cancer to PARP Inhibition

    Yasir H. Ibrahim;Celina García-García;Violeta Serra;Lei He

  • Buparlisib plus fulvestrant versus placebo plus fulvestrant in postmenopausal, hormone receptor-positive, HER2-negative, advanced breast cancer (BELLE-2): a randomised, double-blind, placebo-controlled, phase 3 trial

    José Baselga;Seock Ah Im;Hiroji Iwata;Javier Cortés

  • The Hippo effector YAP promotes resistance to RAF- and MEK-targeted cancer therapies

    Luping Lin;Amit J Sabnis;Elton Chan;Victor Olivas

Frequent Co-Authors

José Baselga
José Baselga Memorial Sloan Kettering Cancer Center
Hope S. Rugo
Hope S. Rugo University of California, San Francisco
Ahmad Awada
Ahmad Awada Université Libre de Bruxelles
Giuseppe Curigliano
Giuseppe Curigliano University of Milan
Joyce O'Shaughnessy
Joyce O'Shaughnessy Baylor University Medical Center
Seock-Ah Im
Seock-Ah Im Seoul National University Hospital
Véronique Diéras
Véronique Diéras Institute Curie
Aleix Prat
Aleix Prat University of Barcelona
Paolo Nuciforo
Paolo Nuciforo Vall d´Hebron Institute of Oncology
Joan Seoane
Joan Seoane Institució Catalana de Recerca i Estudis Avançats

If you think any of the details on this page are incorrect, let us know.

Report an issue

We appreciate your kind effort to assist us to improve this page, it would be helpful providing us with as much detail as possible in the text box below:

Related Online Degrees & Career Pathways

Exploring a future in medicine isn’t limited to the traditional path of becoming a physician. Many related healthcare degrees and career options are available online, offering flexible entry points and faster progression for those seeking to make a difference in healthcare.

For experienced nurses aiming to reach the highest levels of clinical nursing practice, shortest dnp programs provide a streamlined way to earn a Doctor of Nursing Practice in less time. Those who prefer manageable coursework can consider easiest online dnp programs, which balance academic rigor with supportive learning environments.

Entry-level options like lpn programs are ideal for those who want to quickly begin working in the medical field as Licensed Practical Nurses. Meanwhile, for nurses interested in mental health, accelerated msn psychiatric np programs offer a fast track to becoming a specialized nurse practitioner.

Each of these online pathways offers a unique route to impactful, rewarding medical careers for diverse backgrounds and goals.

Best Scientists Citing Javier Cortes

Trending Scientists

Recently Published Articles